Skip to main content
| News

Basel Area treads unique path

05.07.2021

Basel Area Business & Innovation is responsible for both location and innovation promotion. This approach, which is unique across Switzerland, is very successful according to Domenico Scala in a media interview. The president of Basel Area Business & Innovation also discusses future technologies such as digital health and mRNA.

Domenico Scala
Domenico Scala, President of the board of Basel Area Business & Innovation

The Basel Area is the most important life sciences location in Europe, says Domenico Scala in an interview with the HandelszeitungBasel Area Business & Innovation, the location and innovation promotion agency, plays a big part in this. Its work pursues an approach that is unique across Switzerland: linking location and innovation promotion. Scala says that the model works “very well. This means we are able to actively embed companies in the ecosystem while they are being established.”

Scala points to the fact that the Basel Area and the life sciences cluster near Boston play in the same league in terms of research. He adds that the University of Basel and the University Hospital contribute to this. “The Biozentrum at the University of Basel is one of the world’s leading centers for fundamental biomedical research. We have a subsidiary from the ETH Zürich, the Department of Biosystems, and we have several universities.” Scala mentions the Friedrich Miescher Institute and Novartis and Roche’s research facilities. “Around 1000 research groups are active in our region, a critical mass.”

In order for the location to remain strong in the future, engagement in pioneering areas is needed. According to Scala, one of these areas is the digitization of healthcare. “Others are further with this, not just the USA but also other European countries such as Finland and Denmark. Something needs to happen.” Basel Area Business & Innovation is already moving forward with its own initiatives. Scala adds that mRNA is also “an important future technology”. The technology has received support amounting to 50 million Swiss francs from the federal government. However, Scala thinks it is problematic to fund individual projects. Instead, he would like pension funds to be involved in funding startups. “Up to now, only a few tenths of a percent of pension fund assets are invested in venture capital. This needs to change. The money is there, we just need to make sure it is invested correctly.”

From the interview that Sreaina Ursina Gross from the “Handelszeitung” led with Domenico Scala:

The life sciences are an industry of the future, and we are far from exhausting our potential. There are skeptics who say we have a cluster risk.

You see it differently.

If anything, it's a cluster opportunity. Healthcare is the growth industry par excellence. That's because of the demographics, the growth of the middle class in developing countries, and technological advances. We are in a super cycle. Whether it's Basel, Zurich, Zug or Lausanne with the ETH is irrelevant. Of course, in a federal system, there is always some competition for jobs and talent. Everyone is fighting for their tax base. And that's the way it should be. But basically it's good that we have several locations. It makes us stronger in global competition.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

BeiGene opens European headquarters in Basel
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

BeiGene opens European headquarters in Basel

BeiGene has opened its new European headquarters in Basel. The global biotech specializing in innovative cancer treatments intends to build...

Read More
The 25 Best AI Courses in the Basel Area, Germany and France
Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation

The 25 Best AI Courses in the Basel Area, Germany and France

Artificial Intelligence (AI) offers numerous possible applications. But how, where and regarding which focal points can you get further training...

Read More
Engimmune Therapeutics banks 15.5 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Engimmune Therapeutics banks 15.5 million Swiss francs

Engimmune Therapeutics will now be in a position to drive forward its innovative platforms for the development of T-cell therapies...

Read More
Bionter receives 3 million US dollars in investments
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Bionter receives 3 million US dollars in investments

Bionter AG has received 3 million US dollars in a seed funding round. These funds will enable Bionter to bring...

Read More
Resistell seeking to further develop test to combat antibiotic resistance
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Resistell seeking to further develop test to combat antibiotic resistance

The startup Resistell has launched a study looking into the applicability of a test against antibiotic resistances that is being...

Read More
Biotech startup Cimeio receives 46 million Swiss francs for cell therapy
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Biotech startup Cimeio receives 46 million Swiss francs for cell therapy

Cimeio Therapeutics from Basel has received initial financing amounting to 46 million Swiss francs from Versant Ventures. The startup is...

Read More
1 2 3 55

Do you have a question? We'd like to hear from you.